Pharming Group N.V.
PHAR
$16.20
-$0.01-0.06%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | 21.15% | 30.64% | 34.57% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | 21.15% | 30.64% | 34.57% | |
| Cost of Revenue | -- | 40.41% | 24.36% | 72.97% | |
| Gross Profit | -- | 18.94% | 31.43% | 30.81% | |
| SG&A Expenses | -- | 5.23% | 21.84% | 19.56% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -111.45% | 61.41% | 69.82% | |
| Total Operating Expenses | -- | 4.39% | 19.70% | 26.20% | |
| Operating Income | -- | 91.61% | 32.82% | 17.31% | |
| Income Before Tax | -- | 29.30% | 38.71% | 30.19% | |
| Income Tax Expenses | -- | 328.76% | 110.35% | 63.14% | |
| Earnings from Continuing Operations | -- | -12.26% | 19.19% | 18.84% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -12.26% | 19.19% | 18.84% | |
| EBIT | -- | 91.61% | 32.82% | 17.31% | |
| EBITDA | -- | 157.28% | 66.54% | 44.20% | |
| EPS Basic | -- | -13.86% | 23.03% | 23.31% | |
| Normalized Basic EPS | -- | 129.25% | 58.80% | 58.80% | |
| EPS Diluted | -- | -15.20% | 22.99% | 27.40% | |
| Normalized Diluted EPS | -- | 129.25% | 58.80% | 58.80% | |
| Average Basic Shares Outstanding | -- | -3.03% | -3.47% | 4.93% | |
| Average Diluted Shares Outstanding | -- | -3.03% | -3.47% | 2.94% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |